NCT06142188NOT YET RECRUITINGN/ATo evaluate the efficacy and safety of Relmacabtagene Autoleucel in the treatment of adult patients with hematologic malignancies in real-world
Inclusion Criteria: 1. Signed informed consent 2. Patients who have been treated with Relma-cel, including those who have received off-label products; 3. If previously enrolled in another clinical study, they must have completed follow-up in the previous study, or have withdrawn or lost follow-up in the previous study. Exclusion Criteria: 1.Patients who have been treated with Relma-cel and then have been treated with other CAR-T products.
No linked publications found in PubMed